A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia
Desidustat significantly improved Hb levels and accelerated anemia correction in NDD-CKD patients versus placebo, with comparable safety.
Authors
- X. Li (ORCID: https://orcid.org/0000-0002-9728-098X)
- Aicheng Yang
- Changyou Sun (ORCID: https://orcid.org/0000-0002-8784-6767)
- Li Yao (ORCID: https://orcid.org/0000-0001-5725-3031)
- Wenli Chen (ORCID: https://orcid.org/0000-0002-2379-4005)
- Xiaoyan Xiao
- Wenbin Li (92586)
- Qinghong Zhang
- Hua Zhou
- Lin Yang
- Hong Cheng
- Caili Wang
- Aiping Yin
- Zhenhua Yang
- Xiangdong Yang
- Jie Ma
- Jianrong Zhao
- Yan Xu
- Yongjun Shi
- Zhihua Zheng
- Weihong Bi
- Junxia Wang
- Yilan Deng
- Xiaoshi Zhong
- Suhua Li
- Weiji Xie
- Yuanyuan Yin
- Xiaoping Yang
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1159/000551113
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00